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Geneva, Switzerland), multiplexing 12 samples 
during library preparation, with an estimated 
mean coverage of 70X. Variant calling was fil-
tered for variants located in a gene panel of 27 
genes of the coagulation and fibrinolytic path-
ways. The presence of variants in the fibrinogen 
genes was confirmed by Sanger sequencing.
Despite the use of rivaroxaban and aspirin, 
computed tomography angiography (January 
2019) showed large thrombi in several arter-
ies including the ascending aorta (FIGURE 1A –1D). 
The patient was referred for consultations with 
vascular and cardiac surgeons. In March 2019, 
while on rivaroxaban 20 mg per day and aspi-
rin, ischemic stroke with left-sided paresis and 
aphasia occurred due to the right internal carot-
id artery occlusion. The patient was switched to 
apixaban (5 mg twice a day) in combination with 
low -dose aspirin.
The  exome sequencing analysis identified 
a novel heterozygous missense mutation in FGG 
exon 8: c.998 A>G; p.His333Arg (p.His307Arg 
without the signal peptide) which we named Fi-
brinogen Łódź. This mutation, predicted to be 
deleterious by the SIFT prediction algorithm 
and probably damaging by the PolyPhen-2 algo-
rithm, affects the same amino acid as Fibrino-
gen Mannheim II.2
Fibrinogen Łódź is unique due to numerous 
severe arterial thrombotic manifestations in pa-
tients below 50 years of age without any venous 
thrombosis or bleeding and apparent resistance 
to rivaroxaban. Such clinical phenotype in pa-
tients with dysfibrinogenemia is quite uncom-
mon, although 25% of cases of dysfibrinogenemia 
A 51 -year -old woman was referred for thrombo-
philia testing due to recurrent thromboembolism. 
She had 3 episodes of embolism experienced at 
the age below 50 years, namely, to the right bra-
chial artery, to the left external iliac artery and 
the common femoral artery with thromboembo-
lectomy, and to the right popliteal artery. She was 
treated with acenocoumarol (target internation-
al normalized ratio, 2–3). Due to nontherapeu-
tic international normalized ratio values, in 2017 
she was switched to rivaroxaban 20 mg per day 
and aspirin 75 mg per day. The patient had a sin-
gle short episode of paroxysmal atrial fibrillation; 
however, there were no abnormalities on repeat-
ed electrocardiogram, 24 -hour Holter recordings, 
and transthoracic echocardiography. She had 4 
miscarriages and 1 successful pregnancy. Her son 
had myocardial infarction at the age of 23 years. 
At the first clinic visit in August 2018, she was in 
good medical condition. After switching to enoxa-
parin, thrombophilia screening was performed 
with negative results. However, a low fibrinogen 
concentration by von Clauss assay (1.17 g/l [ref-
erence range, 2.1–4.0 g/l]) combined with pro-
longed thrombin time of 22.7 seconds (reference 
range, 10.3–16.6 seconds) and normal fibrino-
gen antigen level determined nephelometrically 
(2.5 g/l; [reference range, 1.8–3.5 g/l]) were found. 
Thrombotic -related dysfibrinogenemia (catego-
ry 3B according to the new classification by Cas-
ini1) was diagnosed in January 2019. To confirm 
it, a whole -exome sequencing analysis was per-
formed at the Health 2030 Genome Center Se-
quencing Platform in Geneva, using Exome Re-
search Reagents (Integrated DNA Technologies, 
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are associated with mainly venous thrombosis, 
for example, Fibrinogen Dusart.3 This case sug-
gests that dysfibrinogenemia should be consid-
ered in patients with arterial thromboembolism 
at an early age. Establishing a proper diagnosis 
of dysfibrinogenemia allows the initiation of an-
ticoagulant therapy and genetic counseling in as-
ymptomatic family members, similarly as in oth-
er thrombophilias.4,5
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FIGURE 1   Computed 
tomography angiography 
in a woman with 
dysfibrinogenemia and 
massive thrombosis in 
the aorta and its 
branches: A – mural and 
mobile thrombus in 
the ascending aorta 
(arrow); B – thrombi in 
the left common carotid 
artery (white arrow) and 
aortic arch (blue arrow); 
C – thrombi in the left 
common carotid artery 
(white arrow), aortic arch 
(blue arrow), aortic arch 
and descending aorta 
(green arrow), and 
descending aorta (yellow 
arrows); D – thrombi in 
the ascending (white 
arrow) and descending 
(blue arrow) aortas
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